Lupin gains on launching combination drugs for heart failure patients

Today, the stock opened at Rs 753.00 and has touched a high and low of Rs 769.70 and Rs 753.00, respectively.

On Wednesday, shares of Lupin closed at Rs 766.90, up by 13.85 points or 1.84% from its previous closing of Rs 753.05 on the BSE.

Lupin has launched combination drugs Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in India. This drug combination is indicated for patients with Heart Failure (HF) conditions. Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg. Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin said, “Heart failure is a difficult condition with severe unmet needs, necessitating the development of treatment agents to improve patient outcomes. As a leader in the cardiac therapy area, Lupin is committed to offering patients with treatment options that limit the need for hospitalization and reduce the risk of death. The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need while reducing the cost of therapy.” 

Lupin is an innovation-led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

The BSE group 'A' stock of face value of Rs 2 has a 52-week high and low of Rs 969.00 and Rs 583.05. Last one week high and low of the scrip stood at Rs 769.70 and Rs 745.15, respectively. The current market cap of the company is Rs 34,875.59 crore.

The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 43.36% and 9.53% respectively.